Drug Trial Radar · NCT00893906
Inactivated Influenza Vaccine Effectiveness in Tropical Africa
Last checked: Nov 20, 2026Latest source record: Sep 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,000
Planned (sponsor's estimate)
Start
May 2009
Primary completion
Dec 2012
Study completion Apr 2013
Sponsor
- Lead sponsor
- PATHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut de Recherche pour le Developpement; Institut Pasteur; Centers for Disease Control and Prevention
- First posted
- May 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 10 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Influenza, a highly communicable acute respiratory disease, is one of the major infectious disease threats to the human population. In Africa, information on the occurrence of influenza and its disease burden is seriously lacking. Such data would be important in determining the contribution of influenza to the more than two million annual pneumonia deaths among children globally, mostly in the developing world, and the potential number of deaths that could be prevented by influenza vaccination. A single dose of trivalent inactivated influenza vaccine (TIV) is 70 to 90 percent effective in preventing influenza in healthy older children and young and middle-aged adults, but is less efficacious in young children and the elderly. Young children who suffer substantial influenza morbidity and are unlikely to have pre-existing immunity should receive two doses of TIV to provide adequate immunity. Because family studies of influenza transmission conducted during the 1970's found children to be the main introducers of influenza into households, vaccination of children may decrease the chances of spreading influenza to contacts. Mass vaccination of schoolchildren has been correlated with reduced respiratory illness in unvaccinated persons suggesting that immunization of children on a larger scale can affect community epidemics. In temperate industrialized countries with seasonal disease, influenza vaccine is given annually, prior to the influenza season, and generally targeted to individuals with the highest risk of severe disease. Influenza prevention strategies may need to differ in tropical developing countries due to a variety of reasons. Given the varying influenza circulation patterns, it is unknown which hemisphere vaccine formulation will provide year-round protection against the diverse strains that may exist in tropical countries. Persons residing in developing countries also may have nutritional deficiencies or underlying diseases and infections that affect vaccine immunogenicity. Consideration must be given to programmatic issues as well. Adolescent and adult preventive health services are poorly developed in many countries, and thus a strategy that targets children may be the most feasible option. In addition, vaccinating children may be the most cost-effective option, as it has the potential to provide direct benefit to those vaccinated, as well as indirect benefits to unvaccinated members of the population. Thus, an influenza vaccine effectiveness study in a tropical developing country population will help to elucidate burden of seasonal influenza and may inform optimal use of vaccine for either seasonal and pandemic situations. Thus, this study in Senegal will to evaluate the direct effects of TIV in reducing the occurrence of laboratory-confirmed influenza among children who receive it as well as the potential indirect effects experienced by the population as a result of reducing transmission among children.
Conditions
- Influenza
Interventions
seasonal trivalent inactivated influenza vaccineBiological
vaccine to be used according to marketed dosage and frequency
inactivated polio vaccineBiological
vaccine to be used according to marketed dosage and frequency
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total effectiveness of vaccine against laboratory-confirmed symptomatic influenza.Time frame: Two weeks post-vaccination through February 28 the following calendar year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Niakhar Demographic Surveillance System
Niakhar, Fatick District, Senegal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.